{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T03:08:06Z","timestamp":1773198486995,"version":"3.50.1"},"reference-count":12,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>\n            Background\u2003In patients with acute venous thromboembolism (VTE), the rates of recurrence and major bleeding are highest during the first weeks of anticoagulation. The CARAVAGGIO trial demonstrated noninferiority of apixaban to dalteparin for treatment of cancer-associated VTE without an increased risk of major bleeding. We compared the early time course of VTE recurrence and major bleeding events of apixaban compared with dalteparin at 7, 30, and 90 days of treatment in patients with cancer-associated VTE.<\/jats:p><jats:p>\n            Methods\u2003The study design of the CARAVAGGIO trial has been described. Eligible patients were randomly assigned to receive monotherapy with either apixaban or dalteparin for 6 months. The primary efficacy outcome was the incidence of objectively confirmed recurrent VTE. The primary safety outcome was major bleeding.<\/jats:p><jats:p>\n            Results\u2003In 1,155 patients, recurrent VTE after 7, 30, and 90 days occurred in 6 (1%), 15 (2.6%), and 27 (4.7%) patients in the apixaban arm versus 5 (0.9%), 20 (3.5%), and 36 (6.2%) patients respectively in the dalteparin arm. By day 7, 30, and 90, major bleeding events had occurred in 3 (0.5%), 9 (1.6%), and 16 (2.8%) patients in the apixaban group versus 5 (0.9%), 11 (1.9%), and 17 (2.9%) patients in the dalteparin group.<\/jats:p><jats:p>\n            Conclusion\u2003The frequencies of recurrent VTE and major bleeding events at 7, 30, and 90 days of apixaban compared with dalteparin were similar in patients with cancer-associated VTE. This supports the use of apixaban for the initiation and early phase of anticoagulant therapy in cancer-associated VTE.<\/jats:p>","DOI":"10.1055\/s-0043-1778642","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T03:42:59Z","timestamp":1704858179000},"page":"676-683","source":"Crossref","is-referenced-by-count":4,"title":["Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer"],"prefix":"10.1055","volume":"124","author":[{"given":"Alexander T.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Haemostasis and Thrombosis, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9591-884X","authenticated-orcid":false,"given":"Katherine J.","family":"Creeper","sequence":"additional","affiliation":[{"name":"Department of Haemostasis and Thrombosis, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom"},{"name":"Haematology Department, Sir Charles Gairdner Hospital, Perth, Australia"},{"name":"Haematology Department, PathWest Laboratory Medicine, Nedlands, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raza","family":"Alikhan","sequence":"additional","affiliation":[{"name":"Haematology Department, University Hospital Wales, Cardiff, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9753-6271","authenticated-orcid":false,"given":"Chaozer","family":"Er","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Woodlands Health, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Brigham and Women's Hospital, Boston, Massachusetts, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[{"name":"Department of Medicine \u2013 Thrombosis and Hemostasis, Leiden University Medical Center, Leiden and Dutch Thrombosis Network, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Munoz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gregorio Mara\u00f1\u00f3n Health Research Institute, Complutense University, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Vescovo","sequence":"additional","affiliation":[{"name":"Department of internal medicine, Ospedale sant Antonio, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-1741","authenticated-orcid":false,"given":"Rupert","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Cardioangiologic Center Bethanien, CCB, Frankfurt, Germany"},{"name":"Center of Thrombosis and Hemostasis, University Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, Universit\u00e0 degli Studi dell'Insubria, Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Agnelli","sequence":"additional","affiliation":[{"name":"Department of internal medicine, Ospedale sant Antonio, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Becattini","sequence":"additional","affiliation":[{"name":"Department of internal medicine, Ospedale sant Antonio, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1160\/TH15-09-0752","article-title":"Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin\/warfarin therapy. A sub-analysis of the AMPLIFY trial","volume":"115","author":"G E Raskob","year":"2016","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"09","key":"ref3","first-page":"1137","article-title":"Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy","volume":"285","author":"J D Douketis","year":"2001","journal-title":"JAMA"},{"issue":"17","key":"ref4","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"09","key":"ref5","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study","volume":"118","author":"G Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref6","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"N Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"issue":"7464","key":"ref7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/bmj.38167.684444.3A","article-title":"The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study","volume":"329","author":"P Prandoni","year":"2004","journal-title":"BMJ"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-0038-1657516","article-title":"Efficacy and safety of oral anticoagulation in patients with cancer","volume":"78","author":"R D Bona","year":"1997","journal-title":"Thromb Haemost"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"287S","DOI":"10.1378\/chest.126.3_suppl.287S","article-title":"Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"M N Levine","year":"2004","journal-title":"Chest"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1538-7836.2010.03852.x","article-title":"Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry","volume":"8","author":"J A Nieto","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1253\/circj.CJ-20-0223","article-title":"Risk factors for major bleeding during anticoagulation therapy in cancer-associated venous thromboembolism - from the COMMAND VTE registry","volume":"84","author":"Y Nishimoto","year":"2020","journal-title":"Circ J"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1055\/s-0040-1720975","article-title":"Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study","volume":"121","author":"W Ageno","year":"2021","journal-title":"Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1778642.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:19:20Z","timestamp":1730801960000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1778642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":12,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2024,6,25]]},"published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1778642","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]}}}